These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 35137496)
1. COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era. Taga A; Lauria G J Peripher Nerv Syst; 2022 Mar; 27(1):4-30. PubMed ID: 35137496 [TBL] [Abstract][Full Text] [Related]
2. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series. Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559 [TBL] [Abstract][Full Text] [Related]
3. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link? Oo WM; Giri P; de Souza A J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. Baars AE; Kuitwaard K; de Koning LC; Luijten LWG; Kok WM; Eftimov F; Wieske L; Goedee HS; van der Pol WL; Blomkwist-Markens PH; Horemans AMC; Jacobs BC; van Doorn PA Neurology; 2023 Jan; 100(2):e182-e191. PubMed ID: 36127144 [TBL] [Abstract][Full Text] [Related]
5. Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023. Jeong YD; Park S; Lee S; Jang W; Park J; Lee K; Lee J; Kang J; Udeh R; Rahmati M; Yeo SG; Smith L; Lee H; Yon DK Sci Rep; 2024 Oct; 14(1):24561. PubMed ID: 39427003 [TBL] [Abstract][Full Text] [Related]
6. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review. Lee HY; Lien WC Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452 [TBL] [Abstract][Full Text] [Related]
7. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study. Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454 [TBL] [Abstract][Full Text] [Related]
8. Chronic inflammatory demyelinating polyneuropathy after SARS-CoV2 vaccination: update of the literature and patient characterization. Ginanneschi F; Vinciguerra C; Volpi N; Piscosquito G; Barone P; Rossi A Immunol Res; 2023 Dec; 71(6):833-838. PubMed ID: 37395901 [TBL] [Abstract][Full Text] [Related]
9. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572 [TBL] [Abstract][Full Text] [Related]
11. Guillain-Barré syndrome in an era of global infections and 21st century vaccination. Lunn MP Curr Opin Neurol; 2022 Oct; 35(5):571-578. PubMed ID: 36069416 [TBL] [Abstract][Full Text] [Related]
12. Guillain-Barre syndrome following COVID-19 vaccines: A review of literature. Yu M; Nie S; Qiao Y; Ma Y Front Immunol; 2023; 14():1078197. PubMed ID: 36875094 [TBL] [Abstract][Full Text] [Related]
13. Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients. Tayebi A; Samimisedeh P; Jafari Afshar E; Mahmoudnia S; Milan N; Ayati A; Madady A; Rastad H BMC Neurol; 2023 Dec; 23(1):437. PubMed ID: 38082244 [TBL] [Abstract][Full Text] [Related]
14. Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review. Abolmaali M; Rezania F; Behnagh AK; Hamidabad NM; Gorji A; Mirzaasgari Z Immunol Res; 2022 Dec; 70(6):752-764. PubMed ID: 36098903 [TBL] [Abstract][Full Text] [Related]
15. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination. Suri V; Pandey S; Singh J; Jena A BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34607818 [TBL] [Abstract][Full Text] [Related]
16. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors. Rzymski P Front Immunol; 2023; 14():1183258. PubMed ID: 37180147 [TBL] [Abstract][Full Text] [Related]